Morgan Stanley Downgrades Infinity Pharmaceutical (INFI) to Equalweight
Tweet
Share
E-mailGet Alerts INFI Hot Sheet
Price: $0.04 --0%
Rating Summary:
12 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 20
Rating Summary:
12 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 20
Join SI Premium – FREE
Morgan Stanley downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Overweight to Equalweight with a price target of $1.00 (from $11.00).
For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.
Shares of Infinity Pharmaceutical closed at $1.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
